-
Signature
-
/s/ Amir Vitale, Attorney-in-Fact
-
Issuer symbol
-
IRWD
-
Transactions as of
-
05 Jan 2026
-
Net transactions value
-
-$162,914
-
Form type
-
4
-
Filing time
-
07 Jan 2026, 16:05:09 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Silver Ronald |
Principal Accounting Officer |
C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON |
/s/ Amir Vitale, Attorney-in-Fact |
07 Jan 2026 |
0001873731 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
IRWD |
Class A Common Stock |
Sale |
$162,914 |
-35,416 |
-11% |
$4.60 |
276,809 |
05 Jan 2026 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: